Belite Bio, Inc
Clinical trials sponsored by Belite Bio, Inc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a pill save your sight? new trial targets blinding eye disease Results expected Jun 2027 (estimated)
-
New hope for rare eye disease: drug trial targets vision loss
Disease control OngoingThis study tests a drug called tinlarebant in 60 people with Stargardt disease, a genetic condition that causes vision loss. The goal is to see if the drug can slow damage to the retina and preserve eyesight. Participants take the drug or a placebo, and researchers measure change…
Phase 2/3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a pill save your sight? new trial targets blinding eye disease
Disease control OngoingThis Phase 3 trial tests whether a daily pill called tinlarebant can slow the growth of geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. About 429 adults with the condition will receive either the drug or a placebo for up to 2 year…
Phase 3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC